SK Acquires BMS Irish Plant To Support Global CMO Leadership Ambitions
Executive Summary
SK Biotek's acquisition of BMS's small molecule API manufacturing plant in Ireland underlines South Korean conglomerate SK Group’s stepped up efforts to grow its biotech and pharma business. The move is in line with SK Biotek's plan to sharply raise revenue and corporate value in the coming years, and the CMO is also considering additional acquisitions or collaborations.
You may also be interested in...
Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing
South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.
SK Acquires AMPAC, On Track To Meet Global Contract Manufacturing Ambitions
With the acquisition of US-based contract development and manufacturing organization AMPAC Fine Chemicals, SK has added the US production base to its European and Korean production facilities, placing it on track to becoming a top global CDMO player with annual production capacity of about 1.6 million liters.
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.